Cargando…
Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937631/ https://www.ncbi.nlm.nih.gov/pubmed/27536454 http://dx.doi.org/10.3109/21556660.2014.960969 |
_version_ | 1782441741745389568 |
---|---|
author | Hosoya, Kei Masuno, Satoru Hashiguchi, Kazuhiro Okubo, Kimihiro |
author_facet | Hosoya, Kei Masuno, Satoru Hashiguchi, Kazuhiro Okubo, Kimihiro |
author_sort | Hosoya, Kei |
collection | PubMed |
description | OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis. RESEARCH DESIGN AND METHODS: Thirty children aged 12–15 years with Japanese cedar pollinosis (positive skin test for Japanese cedar pollen), who had suffered from pollinosis for at least 2 years and developed severe nasal obstruction when exposed to Japanese cedar pollen, were enrolled in this study. They were randomly allocated to treatment with pranlukast or placebo orally after breakfast and dinner for 8 weeks during the Japanese cedar pollen season. Soon after the start of the pollen season, all subjects underwent a challenge by exposure for 3 h to Japanese cedar pollen (8000 grains/m(3)) in an artificial exposure chamber (OHIO chamber). CLINICAL TRIAL REGISTRATION: The University Hospital Medical Information Network in Japan (UMIN000009840). MAIN OUTCOME MEASURES: The effect of pranlukast was evaluated using self-rating of nasal symptoms by the subjects and measurement of eosinophil cationic protein in nasal discharge specimens. RESULTS: Scores for the symptoms of pollinosis were lower in the pranlukast group than in the placebo group during treatment in the priming state, as well as after controlled pollen exposure and natural pollen exposure. Pranlukast significantly improved the score for nasal obstruction, compared with placebo. A correlation was found between changes of the scores for symptoms of pollinosis and changes of the eosinophil cationic protein level. CONCLUSIONS: These results confirm a protective effect of pranlukast against both priming and challenge (controlled and natural) with Japanese cedar pollen. The present findings suggested that pranlukast dry syrup may be useful for prophylaxis against pollinosis in children. |
format | Online Article Text |
id | pubmed-4937631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49376312016-08-17 Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study Hosoya, Kei Masuno, Satoru Hashiguchi, Kazuhiro Okubo, Kimihiro J Drug Assess Original Articles OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis. RESEARCH DESIGN AND METHODS: Thirty children aged 12–15 years with Japanese cedar pollinosis (positive skin test for Japanese cedar pollen), who had suffered from pollinosis for at least 2 years and developed severe nasal obstruction when exposed to Japanese cedar pollen, were enrolled in this study. They were randomly allocated to treatment with pranlukast or placebo orally after breakfast and dinner for 8 weeks during the Japanese cedar pollen season. Soon after the start of the pollen season, all subjects underwent a challenge by exposure for 3 h to Japanese cedar pollen (8000 grains/m(3)) in an artificial exposure chamber (OHIO chamber). CLINICAL TRIAL REGISTRATION: The University Hospital Medical Information Network in Japan (UMIN000009840). MAIN OUTCOME MEASURES: The effect of pranlukast was evaluated using self-rating of nasal symptoms by the subjects and measurement of eosinophil cationic protein in nasal discharge specimens. RESULTS: Scores for the symptoms of pollinosis were lower in the pranlukast group than in the placebo group during treatment in the priming state, as well as after controlled pollen exposure and natural pollen exposure. Pranlukast significantly improved the score for nasal obstruction, compared with placebo. A correlation was found between changes of the scores for symptoms of pollinosis and changes of the eosinophil cationic protein level. CONCLUSIONS: These results confirm a protective effect of pranlukast against both priming and challenge (controlled and natural) with Japanese cedar pollen. The present findings suggested that pranlukast dry syrup may be useful for prophylaxis against pollinosis in children. Taylor & Francis 2014-09-03 /pmc/articles/PMC4937631/ /pubmed/27536454 http://dx.doi.org/10.3109/21556660.2014.960969 Text en © 2014 The Author(s). Published by Taylor & Francis http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Original Articles Hosoya, Kei Masuno, Satoru Hashiguchi, Kazuhiro Okubo, Kimihiro Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title | Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title_full | Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title_fullStr | Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title_full_unstemmed | Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title_short | Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study |
title_sort | placebo-controlled study with ohio chamber of prophylactic pranlukast for children with japanese cedar pollinosis: topic-j iii study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937631/ https://www.ncbi.nlm.nih.gov/pubmed/27536454 http://dx.doi.org/10.3109/21556660.2014.960969 |
work_keys_str_mv | AT hosoyakei placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy AT masunosatoru placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy AT hashiguchikazuhiro placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy AT okubokimihiro placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy |